Deatha Timing of outcome assessment: 12 months · adults meeting 3 or more diagnostic criteria for borderline personality disorder
Brief admission to psychiatric hospital by self‐referral plus… showed no clear difference in deatha Timing of outcome assessment: 12 months compared with treatment (low certainty).
1 finding from 1 review
Self‐harm Measured by: clinicians Timing of outcome assessment: end of treatment · adults meeting 3 or more diagnostic criteria for borderline personality disorder
1 finding from 1 review
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Change in sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse outcomes · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse outcomes · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Recovery of sense of smell (as · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
It is very uncertain whether palmitoylethanolamide and luteolin changes recovery of sense of smell (as compared with no intervention (very low certainty).
1 finding from 1 review
Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of normal olfactory function · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
It is very uncertain whether intranasal steroid spray changes presence of normal olfactory function Assessed by participants as a… compared with no intervention/placebo (very low certainty).
2 findings from 1 review
Other adverse effects · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Presence of normal olfactory function · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
Intranasal steroid drops showed no clear difference in presence of normal olfactory function Assessed by participants > 4… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in sense of smell · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevalence of parosmia · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found